Changes in mast cell number & immunophenotype in patients with mastocytosis treated with avapritinib
Tracy George, MD, The University of Utah, Salt Lake City, UT, discusses the impact of avapritinib therapy for patients with indolent systemic mastocytosis on mast cell numbers and phenotype. Systemic mastocytosis is a rare disease, and in patients with advanced indolent disease, avapritinib, a selective tyrosine kinase inhibitor of activated KIT and PDGFRA, has demonstrated efficacy as evaluated in the PIONEER study (NCT03731260). Avapritinib resulted in a vast reduction in the number of mast cells in patients with indolent systemic mastocytosis and also altered the immunophenotype of aberrant cells. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.
Видео Changes in mast cell number & immunophenotype in patients with mastocytosis treated with avapritinib канала VJHemOnc – Video Journal of Hematological Oncology
Видео Changes in mast cell number & immunophenotype in patients with mastocytosis treated with avapritinib канала VJHemOnc – Video Journal of Hematological Oncology
Показать
Комментарии отсутствуют
Информация о видео
10 апреля 2021 г. 21:00:13
00:03:37
Другие видео канала
![Treatment Options for Systemic Mastocytosis](https://i.ytimg.com/vi/fv7Qd6Bc8KI/default.jpg)
![Mast Cell Activation Symptomatology (Part 3 of 3)](https://i.ytimg.com/vi/ME979bUD1J8/default.jpg)
![Dr. Lee Sees a Patient With Mast Cell Disease | Dr. Pimple Popper](https://i.ytimg.com/vi/IK22bKIuUcM/default.jpg)
![Mast Cell Disease: A Living Nightmare](https://i.ytimg.com/vi/JzsmGUTE3TE/default.jpg)
![Mastocytosis (NORD)](https://i.ytimg.com/vi/DFmDUqIBrOY/default.jpg)
![Living with Systemic Mastocytosis](https://i.ytimg.com/vi/nihNAw9MAAc/default.jpg)
![Mila's Story](https://i.ytimg.com/vi/w9zoBu6OvZs/default.jpg)
![What are Mast Cell Disorders and Mastocytosis?](https://i.ytimg.com/vi/-OUKrd9VOZA/default.jpg)
![Carcinoid Syndrome | Serotonin-Secreting Tumors | 5-Minute Review 🖐](https://i.ytimg.com/vi/Ve_dS8Ft6U8/default.jpg)
![Evaluating serum free light chain ratio as a biomarker for progression to multiple myeloma](https://i.ytimg.com/vi/VnqWPMfmBkw/default.jpg)
![Results from a subgroup analysis of ZUMA-3 and the efficacy of brexu-cel in R/R B-ALL](https://i.ytimg.com/vi/5gIrnHKieBY/default.jpg)
![Overview of Systemic Mastocytosis](https://i.ytimg.com/vi/ukHzKom0mh0/default.jpg)
![The future of MPN treatment: exciting agents and targets being investigated](https://i.ytimg.com/vi/v5JGPrPlags/default.jpg)
![Anne Maitland - Living with Mast Cell Activation Syndrome](https://i.ytimg.com/vi/LddITjni4G0/default.jpg)
![The impact of SF3B1 mutations in myelofibrosis](https://i.ytimg.com/vi/RX2Bv8cM9Dg/default.jpg)
![Mastocytosis (Akin)](https://i.ytimg.com/vi/RPUr_ZdlEhk/default.jpg)
![Ibrutinib's role in CLL treatment and future outlooks](https://i.ytimg.com/vi/o08Lfib8V9w/default.jpg)
![Dr. Peter Vadas - CME Presentation: Mast Cells Gone Wild - Mast Cell Activation Disorders](https://i.ytimg.com/vi/HQQrMcKIOhA/default.jpg)
![Reassessing free light chain criteria used in the diagnosis of MM](https://i.ytimg.com/vi/8bQoL4RQESI/default.jpg)
![Mini-hyper CVD + venetoclax in patients with Ph-ALL](https://i.ytimg.com/vi/uQGDHkbZvng/default.jpg)